Don't Just Read the Abstract Podcast Por Richard Buka arte de portada

Don't Just Read the Abstract

Don't Just Read the Abstract

De: Richard Buka
Escúchala gratis

OFERTA POR TIEMPO LIMITADO | Obtén 3 meses por US$0.99 al mes

$14.95/mes despues- se aplican términos.

Want to stay up-to-date on the very latest developments in non-malignant haematology? Don't have the time or skills to critically appraise important papers? Join Pip and Rich, two haematology doctors on a journey of learning and discovery. Each episode, they will discuss a seminal trial, critically appraise the paper, interview a study author, and discuss the implications of the trial on clinical practice with a subject expert. CPD credits are available from RCPath. The podcast is sponsored by Sobi as a hands-off educational grant. Sobi have no editorial input whatsoever.


This podcast helps you to go beyond the abstract, delving deep into the methods, results, subanalyses, and implications. Interviews with authors gives a real-life perspective on the running of a clinical trial allowing explanations of why they did what they did and good honest discussion on limitations and how they might do it differently next time.

Hosted on Acast. See acast.com/privacy for more information.

Richard Buka Ciencia Higiene y Vida Saludable
Episodios
  • Highlights of 2025 (Episode 2)

    Highlights of 2025 (Episode 2)
    Jan 9 2026
    In this second of a two-part episode, Pip and Rich discuss their highlights of 2025. They discuss a wide range of developments across medical haematology with a focus on red cells disorders and a bit less naval gazing than the first episode.

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
    52 m
  • Highlights of 2025 (Episode 1)

    Highlights of 2025 (Episode 1)
    Dec 26 2025
    In this first of a two-part episode, Pip and Rich discuss their highlights of 2025. They discuss a wide range of developments across medical haematology with a focus on bleeding disorders and immuno-haematology.

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
    56 m
  • Does anyone care about idiopathic and secondary polycythaemia? We do!

    Does anyone care about idiopathic and secondary polycythaemia? We do!
    Dec 9 2025

    On this episode, Pip and Rich discuss two of their recent publications on idiopathic and secondary polycythaemia. The first is an audit across two large hospitals in the Midlands. The team screened over 2000 patients who had had a JAK2 mutation screen performed, eventually finding 266 with confirmed idiopathic or secondary polycythaemia. By the time patients were seen, the haematocrit was already dropping. 60% were never venesected and venesection seemed to make no difference to haematocrits and had no association with thrombotic events. In the second paper which was a survey of clinicans, practice was, as expected, shown to be variable. 85% responded to say that they would be willing to randomise patients to a clinical trial of venesection vs no venesection.


    This is an interesting discussion on a common situation for which there is almost no academic interest whatsoever. However, it is a big clinical problem - there is a lot of work for haematologists here. The evidence does not support treating this group of patients in any way shape or form and a trial to prove non-inferiority of no venesection is very much needed.


    Here are the links to the papers:


    1. Maybury et al. Venesection and resolution of erythrocytosis are not associated with reduced thrombotic risk in secondary and idiopathic polycythaemia: Results from a dual centre, 5-year retrospective study. Br J Haematol . 2025 Sep;207(3):1127-1132. doi: 10.1111/bjh.20235
    2. Nicolson et al. Common Themes and Uncertainties in Management of Secondary Polycythaemia: An International Clinician Survey of Practice. EJHaem . 2025 Oct 27;6(6):e70171. doi: 10.1002/jha2.70171

    Hosted on Acast. See acast.com/privacy for more information.
    Más Menos
    1 h
Todavía no hay opiniones